Dendreon Corporation DNDN
announced today the presentation of data from clinical studies featuring
PROVENGE® (sipuleucel-T), an autologous cellular
immunotherapy for metastatic castrate-resistant prostate cancer (mCRPC),
at the 2013 European Cancer Congress in Amsterdam, September 27-October
1, 2013. Preliminary Phase II data surrounding DN24-02, an
investigational autologous cellular immunotherapy for patients with
surgically resected HER2+ urothelial cancer, will also be presented.
Preliminary data from a Phase II combination study demonstrated that
PROVENGE product potency and immunological prime-boost responses are
maintained when administered concurrently or sequentially with
abiraterone acetate (AA) plus prednisone. Additionally, preliminary data
from an ongoing open-label study of PROVENGE treatment in men with mCRPC
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in